Preclinical safety and efficacy evaluation of the Pipeline Vantage Embolization Device with Shield Technology
Open Access
- 2 June 2020
- journal article
- research article
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 12 (10), 981-986
- https://doi.org/10.1136/neurintsurg-2020-016043
Abstract
Background The Pipeline Vantage Embolization Device with Shield Technology is a next generation flow diverter developed to improve aneurysm occlusion and implant endothelialization in addition to lowering thrombogenicity. We report here the in vivo biocompatibility and in vitro hemocompatibility performance of the Pipeline Vantage Embolization Device with Shield Technology (Vantage) compared with the Pipeline Flex Embolization Device (Flex). Methods Biocompatibility (via histology), aneurysm occlusion and vessel patency (via angiography), and endothelial coverage (via scanning electron microscopy (SEM)) for the Vantage and Flex devices were assessed in the rabbit elastase aneurysm model at 90 days (n=29) and 180 days (n=27). In vitro thrombogenicity for Flex and Vantage (n=16) was assessed using a human blood flow loop model at low heparin concentration (0.6 U/mL) with thrombin generation, platelet activation and thrombus visualization as outputs. Results Raymond Roy Occlusion Classification grade 1 was higher for Vantage (61%) compared with Flex (46%), but was not statistically significant (p>0.05). All branch vessels were patent. Histological measures for both devices were similar (p>0.05). Endothelial coverage of the implant was significantly better for Vantage compared with Flex (p<0.05) for Vantage compared with Flex. High resolution microscopy showed less accumulation of thrombus on Vantage as compared with Flex. Conclusion Vantage improved aneurysm occlusion and implant endothelialization and had significantly lower thrombogenicity as compared with Flex, while preserving the biocompatibility safety profile of Flex.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (1R01NS111119-01A1)
This publication has 25 references indexed in Scilit:
- Analysis of neointima development in flow diverters using optical coherence tomography imagingJournal of NeuroInterventional Surgery, 2017
- Long-Term Clinical and Angiographic Outcomes Following Pipeline Embolization Device Treatment of Complex Internal Carotid Artery Aneurysms: Five-Year Results of the Pipeline for Uncoilable or Failed Aneurysms TrialNeurosurgery, 2016
- Thrombogenicity of flow diverters in an ex vivo shunt model: effect of phosphorylcholine surface modificationJournal of NeuroInterventional Surgery, 2016
- In-vitro thrombogenicity assessment of flow diversion and aneurysm bridging devicesJournal of Thrombosis and Thrombolysis, 2015
- From bench to bedside: utility of the rabbit elastase aneurysm model in preclinical studies of intracranial aneurysm treatmentJournal of NeuroInterventional Surgery, 2015
- Technology developments in endovascular treatment of intracranial aneurysmsJournal of NeuroInterventional Surgery, 2014
- Pipeline for Uncoilable or Failed Aneurysms: Results from a Multicenter Clinical TrialRadiology, 2013
- Hemodynamics and Anatomy of Elastase-Induced Rabbit Aneurysm Models: Similarity to Human Cerebral Aneurysms?American Journal of Neuroradiology, 2011
- A New Endoluminal, Flow-Disrupting Device for Treatment of Saccular AneurysmsStroke, 2007
- Study of the Patency of Small Arterial Branches after Stent Placement with an Experimental in Vivo Model2002